Nucure Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 14-12-2024
- Paid Up Capital ₹ 0.10 M
as on 14-12-2024
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 402.79%
(FY 2022)
- Profit 268.44%
(FY 2022)
- Ebitda -586.74%
(FY 2022)
- Net Worth 47.86%
(FY 2022)
- Total Assets 69.14%
(FY 2022)
About Nucure Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Savita Patel and Avinash Patel serve as directors at the Company.
- CIN/LLPIN
U51909PN2020PTC195477
- Company No.
195477
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Oct 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Nucure Pharmaceuticals Private Limited offer?
Nucure Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Nutraceuticals.
Who are the key members and board of directors at Nucure Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Avinash Patel  | Director | 29-Oct-2020 | Current |
| Savita Patel | Director | 29-Oct-2020 | Current |
Financial Performance of Nucure Pharmaceuticals.
Nucure Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 402.79% increase. The company also saw a substantial improvement in profitability, with a 268.44% increase in profit. The company's net worth Soared by an impressive increase of 47.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nucure Pharmaceuticals?
Unlock access to Nucure Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nucure Pharmaceuticals?
Nucure Pharmaceuticals has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nucure Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nucure Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
